It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Lack or excess expression of the surface ectoderm-expressed transcription factor Grainyhead-like2 (Grhl2), each prevent spinal neural tube closure. Here we investigate the causative mechanisms and find reciprocal dysregulation of epithelial genes, cell junction components and actomyosin properties in Grhl2 null and over-expressing embryos. Grhl2 null surface ectoderm shows a shift from epithelial to neuroepithelial identity (with ectopic expression of N-cadherin and Sox2), actomyosin disorganisation, cell shape changes and diminished resistance to neural fold recoil upon ablation of the closure point. In contrast, excessive abundance of Grhl2 generates a super-epithelial surface ectoderm, in which up-regulation of cell-cell junction proteins is associated with an actomyosin-dependent increase in local mechanical stress. This is compatible with apposition of the neural folds but not with progression of closure, unless myosin activity is inhibited. Overall, our findings suggest that Grhl2 plays a crucial role in regulating biomechanical properties of the surface ectoderm that are essential for spinal neurulation.
Loss or over-expression of Grainyhead-like transcription factors (Grhl) prevents closure of the neural tube but the mechanism underlying this is unclear. Here, the authors show that Grhl2 regulates murine posterior-neuropore closure via changes in the identity and biomechanics of the non-neural, surface ectoderm cells.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details




1 UCL Great Ormond Street Institute of Child Health, University College London, Developmental Biology and Cancer Programme, London, United Kingdom (GRID:grid.83440.3b) (ISNI:0000000121901201)
2 UCL Great Ormond Street Institute of Child Health, University College London, Developmental Biology and Cancer Programme, London, United Kingdom (GRID:grid.83440.3b) (ISNI:0000000121901201); Horizon Discovery, Cambridge, United Kingdom (GRID:grid.450827.c) (ISNI:0000 0004 4651 3231)
3 UCL Infection and Immunity Division, UCL Pathogen Genomic Unit, UCL Cruciform Building, London, United Kingdom (GRID:grid.83440.3b) (ISNI:0000000121901201)
4 UCL Great Ormond Street Institute of Child Health, University College London, Developmental Biology and Cancer Programme, London, United Kingdom (GRID:grid.83440.3b) (ISNI:0000000121901201); Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Avenida Professor Egas Moniz, Lisboa, Portugal (GRID:grid.9983.b) (ISNI:0000 0001 2181 4263)